vTv Therapeutics Inc.

News & Events

Press Releases

In The Media

1. vTv Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

   GlobeNewswire NOV 6, 2025 4:15 PM EST
   Topline Phase 3 CATT1 data for cadisegliatin in type 1 diabetes expected second half 2026 ...
   Read Article

2. vTv Therapeutics Announces New Appointments to its Scientific Advisory Board

   GlobeNewswire OCT 9, 2025 8:00 AM EDT
   HIGH POINT, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-...
   Read Article

3. vTv Therapeutics Will Participate in INNODIA Symposium at the EASD 61st Annual Meeting

   GlobeNewswire SEP 15, 2025 8:00 AM EDT
   HIGH POINT, N.C., Sept. 15, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late...
   Read Article

4. UPDATE -- vTv Therapeutics to Participate in Upcoming September Investor Conferences

   GlobeNewswire SEP 3, 2025 4:57 PM EDT
   HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a...
   Read Article

5. vTv Therapeutics to Participate in Upcoming September Investor Conferences

   GlobeNewswire SEP 3, 2025 8:00 AM EDT
   HIGH POINT, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a...
   Read Article

6. vTv Therapeutics Announces $80 Million Private Placement with Leading Healthcare Institutional Investors and the T1D Fund

   GlobeNewswire SEP 2, 2025 8:00 AM EDT
   Proceeds to fund ongoing CATT1 Phase 3 trial and continued development of cadisegliatin, a novel,...
   Read Article

7. vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

   GlobeNewswire AUG 12, 2025 4:15 PM EDT
   •   First study participant randomized in Phase 3 CATT1 trial evaluating cadiseg...
   Read Article

8. vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin

   GlobeNewswire AUG 11, 2025 8:00 AM EDT
   HIGH POINT, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a ...
   Read Article

9. vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes

   GlobeNewswire AUG 7, 2025 8:00 AM EDT
   HIGH POINT, N.C., Aug. 07, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-...
   Read Article

10. vTv Therapeutics to Participate in the H.C. Wainwright "HCW@Home" Series

    GlobeNewswire JUN 11, 2025 8:00 AM EDT
    HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a ...
    Read Article